Neurocrine Biosciences (NBIX) Tops Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
Go back to Neurocrine Biosciences (NBIX) Tops Q4 EPS by 5c
February 16, 2017 7:47 AM EST
HC Wainwright and Co. analyst Andrew Fein reiterates Buy rating and raises price target on Neurocrine Biosciences (NASDAQ: NBIX) to $100 (from $80), suggesting the company's shares are undervalued by nearly 60%, as proprietary physician surveys help identify the proper value post Opicapone deal.
Fein writes, "Correcting the value proposition surrounding opicapone. In our view, last week's... More
February 15, 2017 7:58 AM EST
Needham & Company analyst Alan Carr reiterates Buy and $62 price target on Neurocrine Biosciences (NASDAQ: NBIX), as the company remains focused on upcoming Ingrezza launch and Phase 2 pediatric Tourette Syndrome data due May 2017.
Carr comments, "Company continues to prepare for Ingrezza launch ahead of... More
February 15, 2017 5:56 AM EST
Baird analyst Brian Skorney reiterates Outperform rating and $66 price target on Neurocrine Biosciences (NASDAQ: NBIX), noting the company reported in-line results ahead of Ingrezza launch.
Skorney comments, "No change to outlook heading into Ingrezza approval. Neurocrine reported a solid end to the year, modestly... More
